Maze Therapeutics Q3 FY25: net loss $30.1M; diluted EPS −$0.66

Key figures from this report

These are the numbers Maze Therapeutics reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$30.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Diluted EPS−$0.66No year-earlier figure tagged10-Q income statement, on EDGAR
3. Cash and cash equivalents$316.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$24.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables